达格列净片致罕见急性胰腺炎及急性肝损伤1例
Rare instances of acute pancreatitis and acute liver injury induced by dapagliflozin tablets:one case report
陈小燕1
作者信息
- 1. 阳泉市第一人民医院药学部,山西阳泉 045000
- 折叠
摘要
达格列净是一种钠-葡萄糖共转运蛋白2抑制剂(sodium-glucose cotransporter2 inhibitors,SGLT2i),2012年作为首个SGLT2i在欧盟批准上市,后于2017年在国内批准上市用于2型糖尿病的治疗.其除有明确的降糖作用外,还可使心血管和肾脏获益,相继在国内获批用于心力衰竭、慢性肾脏病的治疗.随着达格列净的广泛临床应用,其不良反应也逐渐被报道.近年来国外有其致急性胰腺炎的相关报道,国内尚无;其致急性肝损伤的报道目前全球仅见1例.该文报道1例达格列净致急性胰腺炎及急性肝损伤的病例.
Abstract
As one of sodium-glucose cotransporter 2 inhibitors(SGLT2i),dagliflozin was the first SGLT2i agent approved for treating type 2 diabetes mellitus(T2DM)in EU in 2012 and later in China in 2017.In addition to its definite hypoglycemic effect,it has demonstrated promising efficacies for heart failure and chronic kidney disease in China.With its widespread clinical applications,many adverse reactions have been reported.Acute pancreatitis was mentioned in a foreign report.Only one case of acute liver injury was reported glob-ally.Here we described one case of acute pancreatitis and acute liver injury caused by dagliflozin.
关键词
达格列净/急性胰腺炎/急性肝损伤/药品不良反应Key words
dapagliflozin/acute pancreatitis/acute liver injury/adverse drug reaction引用本文复制引用
出版年
2024
NETL
NSTL
万方数据